viewBiocept Inc

Biocept reveals double-digit revenue jump and new Target Selector molecular assay kit

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic.

What's more, Nall says the developer of liquid biopsy tests has released a new Target Selector molecular assay research-use-only kit for clients to use in their own laboratories. The kit will help to detect BRAF mutations, among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.

Quick facts: Biocept Inc

Price: 5.36 USD

Market: NASDAQ
Market Cap: $71.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept reports its liquid biopsy highly accurate in detecting HER2 protein...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the molecular diagnostic assay focused group reported results from a study showing that its Target Selector liquid biopsy was highly accurate in monitoring the HER2 protein alteration in patients with metastatic breast cancer. Nall says...

3 weeks, 4 days ago

2 min read